Clinical implications of T cell exhaustion for cancer immunotherapy
A Chow, K Perica, CA Klebanoff… - Nature reviews Clinical …, 2022 - nature.com
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …
promising immunotherapeutic approach to fight cancers. This approach consists of …
Engineered cellular immunotherapies in cancer and beyond
AV Finck, T Blanchard, CP Roselle, G Golinelli… - Nature medicine, 2022 - nature.com
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang… - Nature, 2022 - nature.com
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
SW Wang, C Gao, YM Zheng, L Yi, JC Lu, XY Huang… - Molecular cancer, 2022 - Springer
Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
Multiple clinical trials of allogeneic T cell therapy use site-specific nucleases to disrupt T cell
receptor (TCR) and other genes,,,,–. In this study, using single-cell RNA sequencing, we …
receptor (TCR) and other genes,,,,–. In this study, using single-cell RNA sequencing, we …
CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
D Gumber, LD Wang - EBioMedicine, 2022 - thelancet.com
Chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment with
enormous potential, demonstrating impressive antitumor activity in the treatment of …
enormous potential, demonstrating impressive antitumor activity in the treatment of …